Dr. Atul Sharma was interviewed in the July 2012 issue of the journal BioPharm Insight on the expansion of Lucentis and Eylea for the treatment of diabetic macular edema.
The article explains that drug company Roche’s Lucentis will most definitely gain US Food and Drug Administration approval in diabetic macular edema, as will Eylea of Regeneron for diabetic macular edema and retinal vein occlusion, according to insiders. But the approval will not change ophthalmologists’ preference for less expensive off-label Avastin.
Dr. Sharma is quoted saying, “Approval for Lucentis in DME is a foregone conclusion. It has the best data for anything in DME at the moment,” he said.
Georgia Retina’s doctors are continually committed to advancing research into treatments for diseases of the retina, and are often consulted by the media for their insight into new therapies.
Dr. Sharma, a board-certified ophthalmologist, graduated with honors from the University of California at Berkeley, before attending Tufts University School of Medicine in Boston. His ophthalmology residency at the University of Pennsylvania Scheie Eye Institute was distinguished by his appointment as Chief Resident. Dr. Sharma completed a two-year vitreoretinal fellowship at the Harvard Medical School, one of the premier fellowship programs in the nation. He has been an active participant in a number of clinical studies, and his publications have appeared in prominent medical journals.
At Georgia Retina, patients’ vision needs are the top priority. As one of the largest retina-only medical practices in the southeastern United States, Georgia Retina specializes in treating diseases of the retina, macula, and vitreous. Its ten board-certified ophthalmologists have received special Fellowship training in vitreo-retinal diseases and surgery, and are engaged in clinical trials with the goal of advancing research into retinal diseases, their causes, and their cures.